Nanobodies as novel agents for cancer therapy (Q30778309)

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

A review of interleukin-2 receptor antagonists in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

The use of basiliximab in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Antibodies in the prevention of renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Antibodies, viruses and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Therapeutic antibodies: magic bullets hit the target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Engineering antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Formatting antibody fragments to mediate specific therapeutic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Making antibodies by phage display technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Escherichia coli secretion of an active chimeric antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

21 January 2018

Engineered antibodies

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Recombinant antibodies for cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Kinetic analysis of recombinant antibody-antigen interactions: relation between structural domains and antigen binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Cloning immunoglobulin variable domains for expression by the polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Loss of splice consensus signal is responsible for the removal of the entire C(H)1 domain of the functional camel IGG2A heavy-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Anatomy of the antibody molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

The crystal structure of a llama heavy chain variable domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Solution structure and backbone dynamics of an antigen-free heavy chain variable domain (VHH) from Llama

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Solution structure of a llama single-domain antibody with hydrophobic residues typical of the VH/VL interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Length distribution of CDRH3 in antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Single domain antibodies: comparison of camel VH and camelised human VH domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

'Camelising' human antibody fragments: NMR studies on VH domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Optimal design features of camelized human single-domain antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Biophysical properties of human antibody variable domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Crystal structure of a shark single-domain antibody V region in complex with lysozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

The fibronectin type III domain as a scaffold for novel binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Antibody phage display technology and its applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Selection and identification of single domain antibody fragments from camel heavy-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Potent enzyme inhibitors derived from dromedary heavy-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Efficient cancer therapy with a nanobody-based conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

By-passing immunization: building high affinity human antibodies by chain shuffling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Single-domain antibody fragments with high conformational stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Stability engineering of antibody single-chain Fv fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Camelid heavy-chain variable domains provide efficient combining sites to haptens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Lateral recognition of a dye hapten by a llama VHH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Bispecific antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Generation of a functional monomolecular protein lattice consisting of an s-layer fusion protein comprising the variable domain of a camel heavy chain antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Crystal structure of the intrinsically flexible addiction antidote MazE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Emergence and evolution of functional heavy-chain antibodies in Camelidae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Intracellularly Expressed Single-Domain Antibody against p15 Matrix Protein Prevents the Production of Porcine Retroviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Intrabodies as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Antigen-independent selection of stable intracellular single-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Trials and tribulations: oncological antibody imaging comes to the fore

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Efficient tumor targeting by single-domain antibody fragments of camels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Bacteria as tumour-targeting vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Structural tolerance of bacterial autotransporters for folded passenger protein domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

PEGylated antibodies and antibody fragments for improved therapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Prolonged in vivo residence times of antibody fragments associated with albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Albumin binding as a general strategy for improving the pharmacokinetics of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Comparison of llama VH sequences from conventional and heavy chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111

Biophysical Properties of Camelid VHHDomains Compared to Those of Human VH3 Domains†

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.111